Insulin-Mediated Down-Regulation of Apolipoprotein A5 Gene Expression through the Phosphatidylinositol 3-Kinase Pathway: Role of Upstream Stimulatory Factor

ABSTRACT The apolipoprotein A5 gene (APOA5) has been repeatedly implicated in lowering plasma triglyceride levels. Since several studies have demonstrated that hyperinsulinemia is associated with hypertriglyceridemia, we sought to determine whether APOA5 is regulated by insulin. Here, we show that cell lines and mice treated with insulin down-regulate APOA5 expression in a dose-dependent manner. Furthermore, we found that insulin decreases human APOA5 promoter activity, and subsequent deletion and mutation analyses uncovered a functional E box in the promoter. Electrophoretic mobility shift and chromatin immunoprecipitation assays demonstrated that this APOA5 E box binds upstream stimulatory factors (USFs). Moreover, in transfection studies, USF1 stimulates APOA5 promoter activity, and the treatment with insulin reduced the binding of USF1/USF2 to the APOA5 promoter. The inhibition of the phosphatidylinositol 3-kinase (PI3K) pathway abolished insulin's effect on APOA5 gene expression, while the inhibition of the P70 S6 kinase pathway with rapamycin reversed its effect and increased APOA5 gene expression. Using an oligonucleotide precipitation assay for USF from nuclear extracts, we demonstrate that phosphorylated USF1 fails to bind to the APOA5 promoter. Taken together, these data indicate that insulin-mediated APOA5 gene transrepression could involve a phosphorylation of USFs through the PI3K and P70 S6 kinase pathways that modulate their binding to the APOA5 E box and results in APOA5 down-regulation. The effect of exogenous hyperinsulinemia in men showed a decrease in the plasma ApoAV level. These results suggest a potential contribution of the APOA5 gene in hypertriglyceridemia associated with hyperinsulinemia.

[1]  L. Pennacchio,et al.  The Liver X Receptor Ligand T0901317 Down-regulates APOA5 Gene Expression through Activation of SREBP-1c* , 2004, Journal of Biological Chemistry.

[2]  K. V. van Dijk,et al.  ApoAV Reduces Plasma Triglycerides by Inhibiting Very Low Density Lipoprotein-Triglyceride (VLDL-TG) Production and Stimulating Lipoprotein Lipase-mediated VLDL-TG Hydrolysis* , 2004, Journal of Biological Chemistry.

[3]  L. Pennacchio,et al.  Analysis of Apolipoprotein A5, C3, and Plasma Triglyceride Concentrations in Genetically Engineered Mice , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[4]  L. Havekes,et al.  The role and mode of action of apolipoproteins CIII and AV: synergistic actors in triglyceride metabolism? , 2004, Current opinion in lipidology.

[5]  Len A Pennacchio,et al.  Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5. , 2004, Biochemical and biophysical research communications.

[6]  X. Prieur,et al.  The Human Apolipoprotein AV Gene Is Regulated by Peroxisome Proliferator-activated Receptor-α and Contains a Novel Farnesoid X-activated Receptor Response Element* , 2003, Journal of Biological Chemistry.

[7]  Medha Kulkarni,et al.  Genetic analysis of a polymorphism in the human apoA-V gene: effect on plasma lipids. , 2003, Journal of lipid research.

[8]  L. Pennacchio,et al.  Apolipoprotein A5, a Crucial Determinant of Plasma Triglyceride Levels, Is Highly Responsive to Peroxisome Proliferator-activated Receptor α Activators* , 2003, The Journal of Biological Chemistry.

[9]  B. Tomlinson,et al.  APOA5‐1131T>C polymorphism is associated with triglyceride levels in Chinese men , 2003, Clinical genetics.

[10]  P. Talmud,et al.  Contribution of APOA5 gene variants to plasma triglyceride determination and to the response to both fat and glucose tolerance challenges. , 2003, Biochimica et biophysica acta.

[11]  J. Ribalta,et al.  The Apolipoprotein AV Gene and Diurnal Triglyceridaemia in Normolipidaemic Subjects , 2003, Clinical chemistry and laboratory medicine.

[12]  R. Schneider-Stock,et al.  Apolipoprotein A-IV mRNA overexpression in early preneoplastic hepatic foci induced by low-number pancreatic islet transplants in streptozotocin-diabetic rats. , 2003, Pathology, research and practice.

[13]  X. Prieur,et al.  The Human Apolipoprotein AV Gene is Regulated by PPAR and Contains a Novel FXR Response Element , 2003 .

[14]  O. eda,et al.  New Apolipoprotein A-V : Comparative Genomics Meets Metabolism , 2003 .

[15]  M. Olivier,et al.  Relative contribution of variation within the APOC3/A4/A5 gene cluster in determining plasma triglycerides. , 2002, Human molecular genetics.

[16]  S. Tomura,et al.  Association found between the promoter region polymorphism in the apolipoprotein A-V gene and the serum triglyceride level in Japanese schoolchildren , 2002, Human Genetics.

[17]  J. Ribalta,et al.  Newly identified apolipoprotein AV gene predisposes to high plasma triglycerides in familial combined hyperlipidemia. , 2002, Clinical chemistry.

[18]  R. Chamuleau,et al.  Adenoviral overexpression of apolipoprotein A-V reduces serum levels of triglycerides and cholesterol in mice. , 2002, Biochemical and biophysical research communications.

[19]  J. Després,et al.  Prevalence of 'hypertriglyceridemic waist' in men who participated in the Quebec Health Survey: association with atherogenic and diabetogenic metabolic risk factors. , 2002, Canadian Journal of Cardiology.

[20]  Geoffrey M Cooper,et al.  Role of mTOR in the degradation of IRS‐1: Regulation of PP2A activity , 2002, Journal of cellular biochemistry.

[21]  Jonathan C. Cohen,et al.  An Apolipoprotein Influencing Triglycerides in Humans and Mice Revealed by Comparative Sequencing , 2001, Science.

[22]  P. Reitsma,et al.  Apolipoprotein A-V A NOVEL APOLIPOPROTEIN ASSOCIATED WITH AN EARLY PHASE OF LIVER REGENERATION* , 2001 .

[23]  P. Cullen.  Evidence that triglycerides are an independent coronary heart disease risk factor. , 2000, The American journal of cardiology.

[24]  V. Laudet,et al.  Circadian and Glucocorticoid Regulation of Rev-erbα Expression in Liver. , 2000, Endocrinology.

[25]  R. O’Brien,et al.  Regulation of Phosphoenolpyruvate Carboxykinase and Insulin-like Growth Factor-binding Protein-1 Gene Expression by Insulin , 2000, The Journal of Biological Chemistry.

[26]  K. Kim,et al.  Regulation of the fatty acid synthase promoter by insulin. , 2000, The Journal of nutrition.

[27]  M. Laakso,et al.  Cardiovascular risk factors clustering with endogenous hyperinsulinaemia predict death from coronary heart disease in patients with Type II diabetes , 2000, Diabetologia.

[28]  P. Woodman,et al.  DNA-binding activity of the transcription factor upstream stimulatory factor 1 (USF-1) is regulated by cyclin-dependent phosphorylation. , 1999, The Biochemical journal.

[29]  D. Brunner,et al.  Elevated serum triglyceride levels and long-term mortality in patients with coronary heart disease: the Bezafibrate Infarction Prevention (BIP) Registry. , 1999, Circulation.

[30]  S. Schreiber,et al.  Protein phosphatase 2A interacts with the 70-kDa S6 kinase and is activated by inhibition of FKBP12-rapamycinassociated protein. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[31]  S. Vaulont,et al.  Essential Role in Vivo of Upstream Stimulatory Factors for a Normal Dietary Response of the Fatty Acid Synthase Gene in the Liver* , 1999, The Journal of Biological Chemistry.

[32]  Randall,et al.  Protein phosphatase 2A interacts with the 70-kDa S6 kinase and is activated by inhibition of FKBP12–rapamycin-associated protein , 1999 .

[33]  H. Sul,et al.  Insulin Stimulation of the Fatty Acid Synthase Promoter Is Mediated by the Phosphatidylinositol 3-Kinase Pathway , 1998, The Journal of Biological Chemistry.

[34]  N. Wong,et al.  Effects of Glucose and Insulin on Rat Apolipoprotein A-I Gene Expression* , 1998, The Journal of Biological Chemistry.

[35]  B. Kahn.  Type 2 Diabetes: When Insulin Secretion Fails to Compensate for Insulin Resistance , 1998, Cell.

[36]  S. Grundy.  Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. , 1998, The American journal of cardiology.

[37]  C. Sutherland,et al.  Activation of the Ras Mitogen-activated Protein Kinase-Ribosomal Protein Kinase Pathway Is Not Required for the Repression of Phosphoenolpyruvate Carboxykinase Gene Transcription by Insulin* , 1998, The Journal of Biological Chemistry.

[38]  B. Spiegelman,et al.  Nutritional and insulin regulation of fatty acid synthetase and leptin gene expression through ADD1/SREBP1. , 1998, The Journal of clinical investigation.

[39]  C. Goding,et al.  Recognition of the E-C4 element from the C4 complement gene promoter by the upstream stimulatory factor-1 transcription factor. , 1997, Journal of immunology.

[40]  D. Wang,et al.  Upstream Stimulatory Factor Binding to the E-box at −65 Is Required for Insulin Regulation of the Fatty Acid Synthase Promoter* , 1997, The Journal of Biological Chemistry.

[41]  J. Goldstein,et al.  The SREBP Pathway: Regulation of Cholesterol Metabolism by Proteolysis of a Membrane-Bound Transcription Factor , 1997, Cell.

[42]  D. Pot,et al.  A specific product of phosphatidylinositol 3-kinase directly activates the protein kinase Akt through its pleckstrin homology domain , 1997, Molecular and cellular biology.

[43]  R. Roth,et al.  Akt, a Pleckstrin Homology Domain Containing Kinase, Is Activated Primarily by Phosphorylation* , 1996, The Journal of Biological Chemistry.

[44]  P. Denéfle,et al.  Protection Against Atherogenesis in Mice Mediated by Human Apolipoprotein A-IV , 1996, Science.

[45]  A. Klippel,et al.  Membrane localization of phosphatidylinositol 3-kinase is sufficient to activate multiple signal-transducing kinase pathways , 1996, Molecular and cellular biology.

[46]  J. Flier,et al.  Insulin Regulation of Phosphoenolpyruvate Carboxykinase Gene Expression Does Not Require Activation of the Ras/Mitogen-activated Protein Kinase Signaling Pathway (*) , 1996, The Journal of Biological Chemistry.

[47]  M. White,et al.  Insulin signal transduction and the IRS proteins. , 1996, Annual review of pharmacology and toxicology.

[48]  B. Burgering,et al.  Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction , 1995, Nature.

[49]  Andrius Kazlauskas,et al.  The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase , 1995, Cell.

[50]  B. Spiegelman,et al.  Dual DNA binding specificity of ADD1/SREBP1 controlled by a single amino acid in the basic helix-loop-helix domain , 1995, Molecular and cellular biology.

[51]  C. Kahn,et al.  Insulin action and the insulin signaling network. , 1995, Endocrine reviews.

[52]  J. Breslow,et al.  Transcriptional regulation of the apoC-III gene by insulin in diabetic mice: correlation with changes in plasma triglyceride levels. , 1994, Journal of lipid research.

[53]  Andrius Kazlauskas,et al.  PDGF- and insulin-dependent pp70S6k activation mediated by phosphatidylinositol-3-OH kinase , 1994, Nature.

[54]  E. Rubin,et al.  Protein composition determines the anti-atherogenic properties of HDL in transgenic mice , 1993, Nature.

[55]  M. T. Kozlowski,et al.  Members of the USF family of helix-loop-helix proteins bind DNA as homo- as well as heterodimers. , 1992, Gene expression.

[56]  J. Castaño.  Regulation of gene expression by insulin. , 1991, Advances in Enzyme Regulation.

[57]  J. Breslow,et al.  Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice. , 1990, Science.

[58]  R. Roeder,et al.  Multiple forms of the human gene-specific transcription factor USF. I. Complete purification and identification of USF from HeLa cell nuclei. , 1988, The Journal of biological chemistry.

[59]  N. Le,et al.  Independent regulation of plasma apolipoprotein C-II and C-III concentrations in very low density and high density lipoproteins: implications for the regulation of the catabolism of these lipoproteins. , 1988, Journal of Lipid Research.

[60]  M. Lefevre,et al.  The role of apolipoprotein A-IV in reverse cholesterol transport studied with cultured cells and liposomes derived from an ether analog of phosphatidylcholine. , 1986, Biochimica et biophysica acta.

[61]  Phillip A. Sharp,et al.  An RNA polymerase II transcription factor binds to an upstream element in the adenovirus major late promoter , 1985, Cell.

[62]  P. Chambon,et al.  Specific interaction between a transcription factor and the upstream element of the adenovirus‐2 major late promoter. , 1985, The EMBO journal.

[63]  R. Roeder,et al.  Interaction of a gene-specific transcription factor with the adenovirus major late promoter upstream of the TATA box region , 1985, Cell.

[64]  G. Schonfeld,et al.  Apolipoprotein C-II and C-III levels in hyperlipoproteinemia. , 1979, Metabolism: clinical and experimental.

[65]  R. DeFronzo,et al.  Glucose clamp technique: a method for quantifying insulin secretion and resistance. , 1979, The American journal of physiology.